C. James

发表

Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways.

C. James, G. Dewald, Xiao-yang Wang, 2002, The American journal of pathology.

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

S. Nelson, C. James, J. Heath, 2014, Science.

Radiation therapy and molecular‐targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges

C. James, P. Houghton, V. Sathiaseelan, 2020, Pediatric blood & cancer.

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models

C. James, C. Horbinski, D. Wainwright, 2017, Neurotherapeutics.

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

S. Gabriel, J. Mesirov, R. Wilson, 2010, Cancer cell.

TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas

Atique U. Ahmed, A. Shilatifard, D. Brat, 2019, Clinical Cancer Research.

Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer

M. Ladanyi, A. Elkahloun, S. Rosenberg, 2011, Science.

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

C. James, N. Sugawa, A. Ekstrand, 1990, Proceedings of the National Academy of Sciences of the United States of America.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.

Sabine Mueller, Haiyun Gan, Nalin Gupta, 2013, Genes & development.

The histone H 3 . 3 K 27 M mutation in pediatric glioma reprograms H 3 K 27 methylation and gene expression

C. James, J. Sarkaria, S. Mueller, 2013 .

H3K27 methylation and gene expression The histone H3.3K27M mutation in pediatric glioma reprograms

C. James, J. Sarkaria, S. Mueller, 2013 .

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

C. James, D. Curiel, C. Horbinski, 2020, bioRxiv.

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

C. James, T. Waldman, S. Mueller, 2014, Nature Medicine.

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

C. James, J. Sarkaria, J. Uhm, 2008, Clinical Cancer Research.

Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms.

C. James, A. Heimberger, Wenjing Xuan, 2021, Trends in immunology.

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas

M. Prados, C. James, W. Weiss, 2016, Oncotarget.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas

M. Berger, C. James, L. Stalpers, 2016, Clinical Cancer Research.

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

Rebecca A. Ihrie, C. James, D. Rowitch, 2012, Proceedings of the National Academy of Sciences.

Targeted Therapy for BRAFV600E Malignant Astrocytoma

Barbara S. Paugh, J. Hodgson, S. Hariono, 2011, Clinical Cancer Research.

Title Targeting PI 3 K in personalized treatment of BRAF-mutated pediatric low-grade gliomas

M. Berger, C. James, L. Stalpers, 2016 .

Targeting PI3K in personalized treatment of BRAF-mutated pediatric low-grade gliomas

C. James, L. Stalpers, M. Berger, 2016 .

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

S. Vandenberg, C. James, R. DePinho, 2012, Proceedings of the National Academy of Sciences.

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

C. James, B. Scheithauer, J. O'fallon, 2001, Journal of the National Cancer Institute.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

S. Vandenberg, M. Prados, Serban Nacu, 2010, Cancer cell.

Improving vaccine efficacy against malignant glioma

C. James, J. Raizer, J. Fangusaro, 2016, Oncoimmunology.

Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells

M. Berger, C. James, S. Bidlingmaier, 2010, Molecular Cancer Therapeutics.

Pleiotropic role for MYCN in medulloblastoma.

S. Vandenberg, C. James, P. Northcott, 2010, Genes & development.

cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma

C. James, A. Heimberger, A. Stegh, 2022, F1000Research.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma

C. James, R. Stupp, Xinghua Lu, 2017, Cancer cell.

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma

C. James, C. Horbinski, J. Phillips, 2021, Neuro-oncology advances.

Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application

C. James, S. Stupp, Mark T. McClendon, 2020, Cancers.

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease

C. James, C. Horbinski, P. Ozark, 2019, Acta Neuropathologica Communications.

Molecular and translational advances in meningiomas.

Arie Perry, Wenya Linda Bi, Felix Sahm, 2019, Neuro-oncology.

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes

A. Shilatifard, C. James, C. Horbinski, 2018, Oncotarget.

An overview of meningiomas.

C. James, C. Horbinski, P. Horowitz, 2018, Future oncology.

Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma

C. Brennan, C. James, Wei Zhang, 2018, Epigenetics.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation

C. James, Seungchan Kim, J. Raizer, 2017, Molecular Cancer Research.

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

M. Prados, C. James, E. Oermann, 2010, Cancer research.

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Matthew J. Brauer, C. James, P. Hegde, 2013, Clinical Cancer Research.

Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

C. James, K. Shokat, M. Feldman, 2010, Science Signaling.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak

Yuan Qi, Jill P. Mesirov, Li Ding, 2010 .

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

C. James, J. Uhm, B. Scheithauer, 2011, International journal of radiation oncology, biology, physics.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Susan M. Chang, S. Vandenberg, M. Prados, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

M. Prados, C. James, John W. Park, 2011, Neuro-oncology.

mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells

M. Berger, C. James, R. Pieper, 2005, Molecular and Cellular Biology.

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

C. James, J. Sarkaria, C. Erlichman, 2005, Neoplasia.

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

C. James, B. Seliger, W. Cavenee, 1991, Cancer research.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma

A. Shilatifard, C. James, C. Horbinski, 2017, Acta neuropathologica communications.

Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups.

D. Brat, K. Aldape, C. James, 2001, The American journal of pathology.

Heparan Sulfate Synthesized by Ext1 Regulates Receptor Tyrosine Kinase Signaling and Promotes Resistance to EGFR Inhibitors in GBM

C. James, J. Phillips, Anupam Kumar, 2020, Molecular Cancer Research.

Proteoglycans and their roles in brain cancer

Aaron E. Robinson, C. Petritsch, J. Phillips, 2013, The FEBS journal.

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

S H Kaufmann, C. James, C. Erlichman, 2001, Cancer research.

Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism.

C. James, Soyeon Park, C. James, 2003, Cancer research.

EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

K. Shokat, Z. Knight, F. McCormick, 2009, Science Signaling.

Circadian regulation of cancer cell and tumor microenvironment crosstalk.

C. James, A. Heimberger, Wenjing Xuan, 2021, Trends in cell biology.

Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1

C. James, D. Louis, D. Gutmann, 2003, Neurology.

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Li Zhang, Howard Colman, Dima Suki, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone morphogenetic protein 4 reduces global H3K4me3 to inhibit proliferation and promote differentiation of human neural stem cells

C. James, J. Kessler, T. Tomita, 2020, bioRxiv.

Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics.

Y. Jan, L. Jan, C. James, 2012, Genes & development.

Sporadic medulloblastomas contain PTCH mutations.

C. James, B. Alderete, R. Jenkins, 1997, Cancer research.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas

Ashley R. Woodfin, A. Shilatifard, N. Kelleher, 2017, Nature Medicine.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

Paul S Mischel, Timothy F Cloughesy, Kenta Masui, 2016, Cancer cell.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

M. Prados, C. James, M. Mehta, 2011, Cancer discovery.

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

C. James, J. Sarkaria, J. Uhm, 2005, Neuro-oncology.

Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts

Nicholas J. Wang, P. Spellman, H. Feiler, 2008 .

Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.

C. James, J. Uhm, R. Rao, 2003, Frontiers in bioscience : a journal and virtual library.

Mitotic recombination of chromosome 17 in astrocytomas.

C. James, W. Cavenee, E. Carlbom, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas.

C. James, B. Scheithauer, J. O'fallon, 1998, International journal of oncology.

Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod

C. James, R. Stupp, D. Wainwright, 2018, Journal of Neuro-Oncology.

EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

Frank McCormick, William A Weiss, David Stokoe, 2009, Science Signaling.

Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging

C. James, S. Nelson, D. Vigneron, 2011, Journal of magnetic resonance imaging : JMRI.

Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.

John Kurhanewicz, Daniel B Vigneron, Sarah J Nelson, 2010, Cancer research.

An LXR agonist promotes GBM cell death through inhibition of an EGFR / AKT / SREBP-1 / LDLR-dependent pathway

M. Prados, C. James, M. Mehta, 2011 .

Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.

Ilwoo Park, John Kurhanewicz, Simon Hu, 2010, Neuro-oncology.

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

L. Chin, C. James, J. Sznajder, 2015, Genes & development.

Clonal genomic alterations in glioma malignancy stages.

C. James, J. Dumanski, W. Cavenee, 1988, Cancer research.

Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment

M. Prados, C. James, I. Smirnov, 2012, Journal of Neuro-Oncology.

An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing

M. Prados, C. James, T. Ozawa, 2012, Journal of Neuro-Oncology.

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity

C. James, A. Ewald, A. Molinaro, 2016, Oncotarget.

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

C. James, J. Uhm, E. Galanis, 2006, Cancer research.

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

C. James, G. Eley, X Y Wang, 2000, Cancer research.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Jane Fridlyand, Justin Chen, Bruno M Costa, 2010, Cancer research.

Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

C. James, D. Curiel, C. Horbinski, 2020, Clinical Cancer Research.

Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells

C. James, P. Fisher, P. Dent, 2005, Oncogene.

Rescue and propagation of fully retargeted oncolytic measles viruses

C. James, S. Russell, K. Peng, 2005, Nature Biotechnology.

Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

C. James, C. Horbinski, G. Kaur, 2019, Clinical Cancer Research.

Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.

C. James, Laura P Serwer, Laura Serwer, 2012, Advanced drug delivery reviews.

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

C. James, R. Stupp, D. Scholtens, 2018, Clinical Cancer Research.

Therapeutic Potential for Bone Morphogenetic Protein 4 in Human Malignant Glioma

C. James, T. Tomita, B. Best, 2017, Neoplasia.

Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

C. James, J. Sarkaria, P. Brown, 2006, Clinical Cancer Research.

WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas

C. James, T. Tomita, C. Jie, 2022, bioRxiv.

Title: WDR82 mediated H3K4me3 is associated with tumor proliferation and therapeutic efficacy in pediatric high-grade gliomas mediated in pediatric H3K4me3 Levels Increase with histopathological malignancy in pediatric gliomas.

C. James, T. Tomita, C. Jie, 2022 .

Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.

C. James, E. Remstein, Paul J. Kurtin, 2000, The American journal of pathology.

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

G. Reifenberger, C. James, L. Liu, 1994, The American journal of pathology.

Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma

C. James, B. Scheithauer, A. D. Dei Tos, 2001, Neurogenetics.

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

C. James, N. Sugawa, A. Ekstrand, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme?

K. Aldape, C. James, B. Scheithauer, 2001, Journal of neuropathology and experimental neurology.

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

C. James, E. Galanis, S. Russell, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era

C. James, A. Heimberger, A. Sonabend, 2022, Frontiers in Immunology.

A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma

Nitya V. Sharma, B. Lai, D. Brat, 2021, Science Translational Medicine.

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum

Karlyne M. Reilly, K. Aldape, C. James, 2002, Oncogene.

Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas

C. James, D. Gutmann, A. Perry, 2001, Neurology.

Amplification of the Platelet‐Derived Growth Factor Receptor‐A (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features

C. James, B. Scheithauer, R. Jenkins, 2000, Journal of neuropathology and experimental neurology.

Glioblastoma as an age-related neurological disorder in adults

L. Hou, C. James, V. Prabhu, 2021, Neuro-oncology advances.

Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy

C. James, T. Tomita, V. Rajaram, 2017, Molecular Cancer.

Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

M. Berger, S. Vandenberg, M. Prados, 2010, Neuro-oncology.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Hanlee P. Ji, M. Berger, S. Vandenberg, 2010, Cancer research.

The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.

C. James, D. Wainwright, O. Bloch, 2016, Immunotherapy.

Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.

C. James, J. O'fallon, R. Jenkins, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification.

V. P. Collins, J. Olson, C. James, 1994, Oncogene.

Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.

J. Olson, C. James, J. He, 1995, Cancer research.

Loss of genetic information in cancer.

C. James, W. Cavenee, M. Hansen, 1989, Ciba Foundation symposium.

Findings of Aberrant Epidermal Growth Factor Receptor in Primary Human Malignant Gliomas

C. James, N. Sugawa, A. Ekstrand, 1991 .

Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.

C. James, G. Eley, T. Magnuson, 2001, Genomics.

Correspondence re: S. Shintani et al., Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res., 59: 4142-4147, 1999.

G. Eley, N. Maihle, J. Reiter, 2000, Cancer research.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

C. James, G. Ahmann, R. Fonseca, 2007, Blood.

Expression in Human Gliomas , and Epidermal Growth Factor and Their α Growth Factor Genes for Epidermal Growth Factor Receptor , Transforming Updated

C. James, B. Seliger, W. Cavenee, 2006 .

Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme

C. James, J. Sarkaria, E. Galanis, 2007, Clinical Cancer Research.

Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla.

M. Berger, C. James, P. Mischel, 2012, Neuro-oncology.

A human brainstem glioma xenograft model enabled for bioluminescence imaging

Michael D. Prados, Tomoko Ozawa, Nalin Gupta, 2009, Journal of Neuro-Oncology.

Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group.

V. P. Collins, C. James, R. Day, 1993, Cancer research.

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

C. James, J. Sarkaria, M. Weller, 2008, Clinical Cancer Research.

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Mitchel S. Berger, William A. Weiss, Mei-Yin Polley, 2011, Neuro-oncology.

Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer.

F. Couch, C. James, R. Jenkins, 1999, Cancer research.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Paul S Mischel, Timothy F Cloughesy, Joseph A Loo, 2009, Cancer research.

The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

C. James, J. Heath, T. Cloughesy, 2013, Clinical Cancer Research.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Zhaoshi Jiang, Somasekar Seshagiri, Franklin Peale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.

F. Couch, C. James, J. Ingle, 2000, Cancer research.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

M. Prados, C. James, J. Sarkaria, 2016, Neuro-oncology.

LY6K Promotes Glioblastoma Tumorigenicity via CAV-1-Mediated ERK1/2 Signaling Enhancement.

C. Brennan, C. James, I. Nakano, 2020, Neuro-oncology.

Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts

Atique U. Ahmed, C. James, J. Sarkaria, 2022, Cancers.

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.

C. James, J. Sarkaria, R. Rao, 2003, Frontiers in bioscience : a journal and virtual library.

p53 in Nonneoplastic Central Nervous System Lesions: An Immunohistochemical and Genetic Sequencing Study

C. James, B. Scheithauer, Ö. Kurtkaya-Yapıcıer, 2002, Neurosurgery.

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.

C. James, I. Pollack, M. Bredel, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.